1984
DOI: 10.1128/aac.26.5.745
|View full text |Cite
|
Sign up to set email alerts
|

Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals

Abstract: Topical treatment, with drug-containing ointments, of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice was studied. Twenty chemotherapeutic agents having potential or established antileishmanial activity were formulated in different ointment and cream bases. Only 15% paromomycin sulfate with 12% methylbenzethonium chloride, 12% benzethonium chloride, 12% cetalkonium chloride, or 12% dimethyl sulfoxide, all incorporated in white soft paraffin (United Kingdom patent application no. 2117237A), we… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
44
0

Year Published

1986
1986
2016
2016

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 108 publications
(50 citation statements)
references
References 10 publications
3
44
0
Order By: Relevance
“…For the past decade, the use of SLN as an alternative carrier for colloidal drug delivery c and d)), respectively, and for the L. tropica amastigote were 1600 μg/ml (panel 2 (f)), 750 μg/ml, and 400 μg/ml (panel 2 (g and h)). Considering the drug's EC 50 , PM-SLN formulations, as in the previous tests, were determined to have a greater inhibitory effect and a significant inhibition of amastigote propagation was observed when the SLN-PM formulation was used compared to PM Effectiveness of topical formulations of 15% PM and 10% urea was reported (9,45,46). Here, we evaluated the in vitro anti-leishmanial activity of PM-SLN formulation against two Leishmania species.…”
Section: Discussionmentioning
confidence: 99%
“…For the past decade, the use of SLN as an alternative carrier for colloidal drug delivery c and d)), respectively, and for the L. tropica amastigote were 1600 μg/ml (panel 2 (f)), 750 μg/ml, and 400 μg/ml (panel 2 (g and h)). Considering the drug's EC 50 , PM-SLN formulations, as in the previous tests, were determined to have a greater inhibitory effect and a significant inhibition of amastigote propagation was observed when the SLN-PM formulation was used compared to PM Effectiveness of topical formulations of 15% PM and 10% urea was reported (9,45,46). Here, we evaluated the in vitro anti-leishmanial activity of PM-SLN formulation against two Leishmania species.…”
Section: Discussionmentioning
confidence: 99%
“…PM, like all the aminoglycoside antibiotics, inhibits protein biosynthesis in sensitive organisms (1). PM ointments were shown to be effective in an experimental model of murine leishmaniasis (17,38,39). The results of most clinical trials showed an acceptable level of efficacy of PM for the treatment of CL, especially lesions caused by L. major (5,43).…”
Section: Vol 53 2009 Topical Liposomal Paromomycin For Leishmaniasimentioning
confidence: 99%
“…In 1984, El-On and colleagues (17) described the activity of 15% PM plus 12% methylbenzethonium chloride in soft paraffin and it was marketed in Israel, but clinical studies of this formulation reported that it induced local toxicity and was not well tolerated (2,13).…”
Section: Vol 53 2009 Topical Liposomal Paromomycin For Leishmaniasimentioning
confidence: 99%
“…Different formulations (mixture) of paromomycin ointments (15-20%) with/without MBCL (12%) or urea (10%) were introduced but the results were equivocal and were not convincing (Grogl et al, 1999;Arana et al, 2001b). Adding 12% concentration of benzethonium chloride, cetalkonium chloride or dimethyl sulfoxide, all incorporated in white soft paraffin, could effectively cure the disease or healed the lesion significantly in BALB/c mice (El-On et al, 1984). Although many trials were undertaken, it is very difficult to comparatively discuss them (Arana et al, 2001b).…”
Section: Paromomycinmentioning
confidence: 99%